Werewolf Therapeutics (HOWL) reported second-quarter 2026 financial results, including $21.0 million in collaboration revenue and net income of $3.7 million. The revenue was recognized in connection with the company’s agreement to sell its JZP898 program to Jazz Pharmaceuticals Ireland Limited.
The company said it repaid all amounts owed under its loan and security agreement with K2 HealthVentures and continues to evaluate strategic alternatives with Piper Sandler. Werewolf also said it expects to provide updates in the second half of the year on that process and on clinical trials of WTX-124 and WTX-330.
- Cash and cash equivalents were $22.0 million as of June 30, 2026, compared with $46.5 million as of March 31, 2026.
- Research and development expenses were $6.2 million, down from $13.1 million in the year-earlier quarter.
- General and administrative expenses were $7.7 million, compared with $4.4 million in the same period of 2025.
- Net income was $3.7 million, compared with a net loss of $18.0 million a year earlier.
- The company expects its current operating plan to fund operations into the second quarter of 2027.
$HOWL Insider Trading Activity
$HOWL insiders have traded $HOWL stock on the open market 43 times in the past 6 months. Of those trades, 0 have been purchases and 43 have been sales.
Here’s a breakdown of recent trading of $HOWL stock by insiders over the last 6 months:
- LUKE EVNIN has made 0 purchases and 29 sales selling 1,752,286 shares for an estimated $897,297.
- CAPITAL MANAGEMENT, L.P. RA has made 0 purchases and 14 sales selling 1,543,973 shares for an estimated $573,245.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$HOWL Hedge Fund Activity
We have seen 15 institutional investors add shares of $HOWL stock to their portfolio, and 23 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SQUADRON CAPITAL MANAGEMENT LLC added 563,535 shares (+inf%) to their portfolio in Q1 2026, for an estimated $469,199
- BANK OF AMERICA CORP /DE/ removed 472,967 shares (-64.1%) from their portfolio in Q1 2026, for an estimated $393,792
- MPM BIOIMPACT LLC removed 184,747 shares (-13.3%) from their portfolio in Q1 2026, for an estimated $153,820
- RENAISSANCE TECHNOLOGIES LLC removed 161,548 shares (-23.8%) from their portfolio in Q1 2026, for an estimated $134,504
- ALYESKA INVESTMENT GROUP, L.P. removed 149,151 shares (-63.3%) from their portfolio in Q1 2026, for an estimated $124,183
- MILLENNIUM MANAGEMENT LLC removed 108,059 shares (-45.0%) from their portfolio in Q1 2026, for an estimated $89,969
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 99,829 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $83,117
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
